Company: NIVFW
Filing Date: 2025-10-31
Form Type: 424B3
Source: 0001213900-25-104469
Chunk: 61

Company: NewGenIvf Group Ltd
Filing Date: 2025-10-31
Form: 424B3
Chunk 61
---

 a result of more products and procedures receiving regulatory approval or otherwise free to market in international markets; |

| ● | longer accounts receivable                                         
 payment cycles and difficulties in collecting accounts receivable; |

| ● | reduced or varied protection                        
 for intellectual property rights in some countries; |

| ● | export restrictions, trade         
 regulations, and foreign tax laws; |

| ● | fluctuations in currency 
 exchange rates;          |

| ● | foreign certification and                      
 regulatory clearance or approval requirements; |

| ● | customs clearance and shipping 
 delays;                        |

| ● | political, social, and                                                            
 economic instability abroad, terrorist attacks, and security concerns in general; |

| ● | preference for locally 
 provided services;     |

| ● | potentially adverse tax                                                      
 consequences, including the complexities of foreign value-added tax systems; |

| ● | the burdens of complying                                               
 with a wide variety of foreign laws and different legal standards; and |

| ● | increased financial accounting          
 and reporting burdens and complexities. |

If one or more of these risks
are realized, its business, financial condition and results of operations could be adversely affected.

Ethical, legal and social concerns related to the use of assisted reproductive technology could reduce demand for the fertility services provided by the medical facilities in NewGenIvf’s network, and thus may adversely affect the business, financial conditions and results of operations of the medical facilities in its network.

Patient sentiment and distrust
of the use of assisted reproductive technology may lead to less demand for fertility services. Assisted reproductive technologies, including
genetic testing, technologies used for surrogacy and egg donation and gender selection, have raised ethical, legal and social issues
regarding privacy and the appropriate uses of the resulting information. Government authorities could, for social or other purposes,
limit or regulate the use of assisted reproductive technology to certain conditions. Similarly, these concerns may lead patients to refuse
to use, or physicians to be reluctant to order, assisted reproductive services even if permissible. These and other ethical, legal and
social concerns may limit market acceptance of fertility services or reduce patient demand for such services, either of which could have
a material adverse effect on the business, financial condition and results of operations of the medical facilities in NewGenIvf’s
network, and NewGenIvf itself.

<div align='center'>35</div>

NewGenIvf is reliant on revenue from international clients.

Fertility services revenue
from international clients are an important part of NewGenIvf’s revenue, though